01:05 PM EDT, 03/18/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We reduce our 12-month target to $126 from $139, 20.4x our FY 26 EPS estimate. This is below A's five-year forward P/E average of 26.8x, but justified by the company's moderate growth outlook in a challenging operating environment. We retain our FY 2025 EPS at $5.59 and lower FY 26's to $6.18 from $6.26. We continue to see limited upside potential at current levels as we expect near-term uncertainties in the funding environment in the U.S. to persist. At a recent investor conference, CEO Padraig McDonell acknowledged that in January, A saw some slowdown as their clients tried to gauge the impact of on-going uncertainties for existing and future research grants. At the same time, while the impacts of the recently imposed tariffs on Mexico and Canada will be limited, according to the company, we think escalating U.S.-China trade tensions could pose a more substantial risk to A, especially if China takes potential retaliatory actions directly targeting life sciences tools and services companies, in our view.